Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry

Juergen Behr, Marius M Hoeper, Michael Kreuter, Jens Klotsche, Hubert Wirtz, David Pittrow, Juergen Behr, Marius M Hoeper, Michael Kreuter, Jens Klotsche, Hubert Wirtz, David Pittrow

Abstract

Background: Guidelines on the diagnosis and management of idiopathic pulmonary fibrosis (IPF), a rare manifestation of chronic progressive fibrosing interstitial pneumonia, have been updated by ATS/ERS/JRS/ALAT in 2011. In Europe, data are limited on the characteristics and management of such patients.

Methods/design: Investigating significant health trends (INSIGHTS)-IPF is a prospective observational longitudinal registry designed to describe the characteristics and management of newly diagnosed (incident) and prevalent patients with IPF on the long term. The registry uses a non-probability sampling approach to collect data on characteristics, therapeutic interventions, health-related quality of life and health economic parameters. At least 500 patients in ambulatory care will be included consecutively in about 30 centres. The study has been initiated in November 2012, and currently (December 2013) follows 344 patients. ClinTrials.gov identifier is NCT01695408.

Discussion: INSIGHTS-IPF documents one of the largest IPF cohorts in Europe. The registry is expected to provide much-needed data on the characteristics and management situation of patients with IPF in Germany. It will allow comparisons with other countries. Gap analyses based on current guidelines for management of these patients will be possible.

Keywords: Interstitial Fibrosis; Rare lung diseases.

References

    1. Raghu G, Collard HR, Egan JJ, et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824
    1. Coultas DB, Zumwalt RE, Black WC, et al. . The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967–72
    1. Gribbin J, Hubbard RB, Le Jeune I, et al. . Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980–5
    1. Raghu G, Weycker D, Edelsberg J, et al. . Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810–16
    1. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 1990;301:1015–17
    1. Iwai K, Mori T, Yamada N, et al. . Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994;150:670–5
    1. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003;97:428–35
    1. Karakatsani A, Papakosta D, Rapti A, et al. . Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122–9
    1. Raghu G. Idiopathic pulmonary fibrosis. A rational clinical approach. Chest 1987;92:148–54
    1. Selman M, Carrillo G, Estrada A, et al. . Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE 2007;2:e482.
    1. Song JW, Hong SB, Lim CM, et al. . Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356–63
    1. National Heart Lung and Blood Institute (NHLBI). Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful (NIH News, 21. Oct 2011). (accessed 27 Jul 2013)
    1. European Medicines Agency (EMA). Esbriet. CHMP Public Assessment Report EMA/CHMP/115147/2011. London, 2010. (accessed 10 Dec 2013)
    1. Richeldi L, Costabel U, Selman M, et al. . Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079–87
    1. Koller M, Neugebauer EA, Augustin M, et al. . [Assessment of quality of life in health services research—conceptual, methodological and structural prerequisites]. Gesundheitswesen 2009;71:864–72
    1. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79.
    1. Szende A, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health 2005;8:534–48
    1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden 3.0 vom 27.5. 2008. (acessed 10 Dec 2013)
    1. National Institute for Clinical Excellence (NICE). Guide to the methods of technical appraisal. London: NICE, 2004. (accessed 10 Dec 2013)
    1. Anonymous. SF-36. US Population Norm Values. 1998. (accessed 10 Dec 2013)
    1. Morfeld M, Bullinger M, Nantke J, et al. . [The version 2.0 of the SF-36 Health Survey: results of a population-representative study]. Soz Praventiv Med 2005;50:292–300
    1. Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 2010;188:125–32
    1. Fioret D, Mannino D, Roman J. In-hospital mortality and costs related to idiopathic pulmonary fibrosis between 1993 and 2008 (abstract 1038A). Chest 2011;140
    1. Wilson JW, du Bois RM, King TE, Jr. Challenges in pulmonary fibrosis: 8—the need for an international registry for idiopathic pulmonary fibrosis. Thorax 2008;63:285–7
    1. Alpert JS. Are data from clinical registries of any value? Eur Heart J 2000;21:1399–401
    1. European Society of Cardiology. Registries, Databases, Protocols and Surveys. (accessed 10 Dec 2013)
    1. Hoeper MM, Huscher D, Ghofrani HA, et al. . Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol 2013;16:871–80
    1. Guenther A, Eickelberg O, Preissner KT, et al. . International registry for idiopathic pulmonary fibrosis. Thorax 2008;63:841; author reply 841
    1. European Commission. EurIPFnet European IPF Network: natural course, pathomechanisms and novel treatment options in idiopathic pulmonary fibrosis. (accessed 10 Dec 2013)
    1. Glatz U. [GOLDnet—focus on rare lung diseases]. Dtsch Med Wochenschr 2011;136:p10.
    1. Greiner W, Weijnen T, Nieuwenhuizen M, et al. . A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222–31
    1. Brook RH, McGlynn EA, Cleary PD. Measuring quality of care—part two of six. N Engl J Med 1996;335:966–70
    1. Eakin EG, Resnikoff PM, Prewitt LM, et al. . Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998;113:619–24
    1. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2:105–10
    1. Kupferberg DH, Kaplan RM, Slymen DJ, et al. . Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005;25:370–7
    1. Swigris JJ, Brown KK, Behr J, et al. . The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296–304
    1. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA (Medical Dictionary for Regulatory Activities). Internet: (accessed 10 Dec 2013)
    1. Gitt AK, Bueno H, Danchin N, et al. . The role of cardiac registries in evidence-based medicine. Eur Heart J 2010;31:525–9
    1. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005;14:589–95
    1. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58:635–41
    1. Behr J, Hoeper MM, Kreuter M, et al. . [Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Dtsch Med Wochenschr 2012;137:2586–8
    1. Quanjer PH, Tammeling GJ, Cotes JE, et al. . Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe